Sabby Management’s Heron Therapeutics HRTX Stock Holding History

Sabby Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-160,323	Closed	-$4.29M	–	344
2015 Q3	$3.91M	Buy	+160,323	New	+$5.34M	0.16%	100
2015 Q1	–	Sell	-162,900	Closed	-$1.84M	–	310
2014 Q4	$1.64K	Sell	162,900 -22,100	-12%	-$180K	0.05%	139
2014 Q3	$1.54K	Buy	185,000 +49,719	+37%	+$463K	0.06%	131
2014 Q2	$1.67M	Buy	+135,281	New	+$1.62M	0.07%	114

Other funds holding HRTX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Sabby Management's HRTX Position: Q4 2015 in Review

Sabby Management sold out of Heron Therapeutics (HRTX) in Q4 2015, closing a stake of 160,323 shares — an estimated $4.29M sold.

Sabby Management first reported a position in HRTX in Q2 2014 and held it in 4 quarters. The position peaked at $3.91M in Q3 2015. 107 funds tracked by Wall St. Rank hold HRTX as of Q4 2015.

Sabby Management reported no remaining Heron Therapeutics position as of Q4 2015 after selling out during the quarter.
Sabby Management sold 160,323 Heron Therapeutics shares in Q4 2015, an estimated $4.29M.
Sabby Management first reported a position in Heron Therapeutics in Q2 2014 and held it in 4 quarters.
Sabby Management's Heron Therapeutics position peaked at $3.91M in Q3 2015.
107 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2015.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.